BOSTON--(BUSINESS WIRE)--Mytide Therapeutics, a biotechnology company leveraging the power of machine learning to overcome barriers in peptide development, today announced the availability of its industrialized platform to companies pursuing neoantigens, novel peptides, modified peptides and natural peptide therapies. The company has opened access to its RACE platform to accelerate peptide production and shorten the timeline to clinical use.
Mytide is the first company to take a holistic approach to peptide synthesis through the development of technologies to eliminate common and long-standing manufacturing and purification bottlenecks that presently limit researchers’ and companies’ accessibility to the biologically active molecules.
“Historically, peptide development and manufacturing are time consuming and expensive processes, relying on manual approaches that have not seen major technological developments in several decades,” said Dale Thomas, Cofounder. “Our platform represents a significant technological breakthrough, minimizing the need for manual synthesis and enabling end-to-end automated manufacturing at high throughputs and high quality through the use of AI.”
Mytide’s reliable, automated platform offers measurable improvements in manufacturing speed, up to 30 times faster than traditional synthesis, equating to the delivery of hundreds of peptides within a week, compared to the current timeline of 30 to 75 days. Additionally, Mytide is developing advanced manufacturing techniques to increase the discoverable sequences space and meet the potential growth in both innovation and commercialization.
David Hart, Professor of Manufacturing Engineering at MIT states, “Mytide’s novel integration of robotics, AI, and industry 4.0 methodologies represents a breakthrough, enabling them to overcome the complexities of peptide manufacturing. This approach solves persistent manufacturing challenges as companies seek scalable solutions to meet the demand for new personalized therapies.”
Thomas added, “Wide recognition of the speed and savings associated with the RACE platform has begun with several of the world’s leading vaccine and neoantigen companies participating in our platform’s beta program. We’ve streamlined a cumbersome process and eliminated complexity by leveraging robots and AI, and we look forward to welcoming additional partners who can take advantage of this approach”.
With 140+ peptide treatments in the clinic across a variety of therapeutic areas and another 500 in the preclinical stage, there is a significant opportunity for growth. Obstacles to maximizing this growth persist, but Mytide’s approach enables the acceleration of discovery and development of peptides for serious illnesses, ranging from cancer to inflammatory disorders to infectious disease, while also enabling improvements in personalization and customization.
About Mytide Therapeutics
Mytide Therapeutics is focused on industrializing the production of peptides and proteins, an important class of therapeutics for a wide variety of serious conditions, ranging from cancer to inflammatory disorders and infectious diseases. Mytide’s next-generation manufacturing platform RACE, standing for rapid automated computation, coupling, cleavage, chromatograph execution platform, is capable of rapidly producing peptides more efficiently and cost-effectively. Mytide works closely with partners to overcome challenges producing both peptide and protein libraries with considerable complexity. For more information about partnering with Mytide, visit https://www.mytide.io.
